Sustained Impairment of Pituitary and Testicular Function in Prostatic Cancer Patients Treated with a Depot Form of a GnRH Agonist

1988 ◽  
Vol 30 (1) ◽  
pp. 22-25 ◽  
Author(s):  
Ermanno Rolandi ◽  
Roberto Franceschini ◽  
Claudio Giberti ◽  
Teresa Brancadoro ◽  
Giuseppe Martorana ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Gnrh Agonist ◽  
Prostatic Cancer ◽  
Testicular Function ◽  
Depot Form

scholarly journals Effect of oestrogen on liver function of prostatic cancer patients

BMJ ◽  
1969 ◽  
Vol 4 (5677) ◽  
pp. 204-205 ◽  
Author(s):  
M. Kontturi ◽  
E. Sotaniemi
Keyword(s):  
Liver Function ◽  
Cancer Patients ◽  
Prostatic Cancer

PSA and radicai prostatectomy

1995 ◽  
Vol 62 (3) ◽  
pp. 422-424
Author(s):  
F. Zattoni
Keyword(s):  
Cancer Patients ◽  
Metastatic Disease ◽  
Adjuvant Treatment ◽  
Prostatic Cancer ◽  
Prostatic Tissue ◽  
Reliable Marker

PSA represents a very reliable marker in the evaluation of prostatic cancer patients. Particularly in those who have undergone radicai prostatectomy, finding dosable values of serum PSA, that theoretically shouldn't occur, must be regarded as the persistence, at least, of residuai prostatic tissue. An increase of such concentrations raises doubts of locai recurrence or metastatic disease. Every effort must be made to demonstrate this event as soon as possible in order to apply an adjuvant treatment. Non-disappearance of serum PSA at 3 months after surgery has to be inevitably considered as a lack of surgical radicality.

Treatment of Prostatic Cancer with a Depot Form of a Luteinizing Hormone-Releasing Hormone Analogue

1986 ◽  
Vol 12 (6) ◽  
pp. 390-394 ◽  
Author(s):  
L. Giuliani ◽  
T. Barreca ◽  
C. Giberti ◽  
R. Franceschini ◽  
G. Martorana ◽  
...  
Keyword(s):  
Luteinizing Hormone ◽  
Prostatic Cancer ◽  
Hormone Analogue ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Depot Form
Sign in / Sign up

Export Citation Format

Share Document